Post-Market Clinical Follow-Up study for Microneedling devices revive mn” and revive” - MT-MN-02

MT.DERM GmbH0 个研究点目标入组 56 人开始时间: 2018年2月3日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•presence of post-acne facial atrophic scars,
•- age between 18–65 years,
•- voluntary participation,
•- ability to comprehend and provide informed consent,
•- agreement not to participate in another clinical study and to undergo other treatments during the study
•- agreement NOT to use any topical agents that influence appearing of acne scarring, such as peeling or active ingredients like Retinoids during the study period.
•- agreement NOT to undergo any aesthetic treatments (such as Botox, fillers, microdermabrasion, laser treatment etc.) in the treatment area, during the study period.

•- Haemophilia / bleeding disorder
•- Uncontrolled diabetes mellitus
•- Treatment of eye ball or mucosa
•- Treatment of skin areal with dermatosis, e.g. skin tumor, keloid (or extreme keloidal tendency), solar keratosis, warts or birth marks
•- anticoagulant therapy, e.g. warfarin, heparin, salicylic acid
•- chemotherapy, radiotherapy or high doses of cortico-steroids
•- Systemic infection (e.g. hepatitis) or acute skin infection (e.g. herpes)
•- Any form of active acne
•- Allergic reaction to topic and local anesthetics
•- Pregnancy and lactation
•- Eczema, exanthema or open wounds
•- Scars not older than 6 months
•- Skin areal with plastic surgery in the past 12 months
•- Skin areal with filler injection in the past 6 months.

发起方

MT.DERM GmbH